LENZ Therapeutics Stock In Shambles: Down -42% With 10-Day Losing Streak
LENZ Therapeutics (LENZ) stock hit day 10 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -42% return. The company has lost about $944 Mil in value over the last 10 days, with its current market capitalization at about $1.3 Bil. The stock remains 43.3% below its value at the end of 2024. This compares with year-to-date returns of 14.3% for the S&P 500.
LENZ Therapeutics’ recent streak reflects investor apprehension after an FDA adverse event report cited a retinal tear in a patient using its Vizz eye drops. Though the company emphasized the patient’s pre-existing conditions and analysts suggested an overreaction, the news overshadowed Vizz’s early commercial rollout, despite positive feedback on efficacy.
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact.For quick background, LENZ is a biopharmaceutical company developing and commercializing vision-improving therapies, including Phase III candidates LNZ100 and LNZ101 for presbyopia treatment in the United States.
Comparing LENZ Stock Returns With The S&P 500
- Is the Arista Rally Over? The Path to $111
- Get Paid 12% To Buy AVGO At A 30% Discount – Here’s How
- Is United Rentals Stock Utilizing Systematic Share Retirement for Long-Term Alpha?
- Micron Stock Surged 9x But History Suggests Caution.
- Can LRCX Stock Live Up To Its Multiple?
- Does Exxon Mobil Stock Still Have Room to Run?
The following table summarizes the return for LENZ stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | LENZ | S&P 500 |
|---|---|---|
| 1D | -2.0% | -1.2% |
| 10D (Current Streak) | -41.5% | -1.9% |
| 1M (21D) | -36.3% | 0.7% |
| 3M (63D) | -60.7% | 1.3% |
| YTD 2025 | -43.3% | 14.3% |
| 2024 | 1001.9% | 23.3% |
| 2023 | -21.1% | 24.2% |
| 2022 | -73.3% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 24 S&P constituents with 3 days or more of consecutive gains and 63 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 9 | 17 |
| 4D | 2 | 35 |
| 5D | 2 | 9 |
| 6D | 5 | 0 |
| 7D or more | 6 | 2 |
| Total >=3 D | 24 | 63 |
Key Financials for LENZ Therapeutics (LENZ)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-72.4 Mil | $-58.6 Mil |
| Net Income | $-70.0 Mil | $-49.8 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $5.0 Mil | $12.5 Mil |
| Operating Income | $-16.9 Mil | $-18.9 Mil |
| Net Income | $-14.9 Mil | $-16.7 Mil |
The losing streak LENZ stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.